Trevi Therapeutics Inc - Company Profile
Powered by 
All the data and insights you need on Trevi Therapeutics Inc in one report.
$295
- Save hours of research time and resources with
our up-to-date Trevi Therapeutics Inc Strategy Report
- Understand Trevi Therapeutics Inc position in the market,
performance and strategic initiatives.
- Gain competitive edge and increase your
chances of success
Trevi Therapeutics Inc (Trevi Therapeutics) is a clinical-stage biopharmaceutical company. It offers the product Haduvio which uses for the treatment of serious cough conditions including IPF, interstitial lung diseases, and refractory chronic cough. The company offers nalbuphine ER as its pipeline product. Its product is being developed for treating patients with prurigo nodularis, pruritus in chronic liver disease, chronic cough related to idiopathic pulmonary fibrosis (IPF) and levodopa-induced dyskinesia (LID). It operates across the US. Trevi Therapeutics is headquartered in New Haven, Connecticut, the US.
Headquarters
United States of America
Address
195 Church St Fl 14, New Haven, Connecticut, 06510-2009
Telephone
1 203 3042499
No of Employees
25
Industry
Pharmaceuticals and Healthcare
Ticker Symbol & Exchange
TRVI (NASD)
EPS
XYZ
Net Income (2022)
XYZ
0.3%
(2022 vs 2021)
Market Cap*
$175.2M
* As of and is in US$
Trevi Therapeutics Inc premium industry data and analytics
Products and Services
| Products |
|---|
| Haduvio |
| Nalbuphine ER |
Competitor Comparison
| Key Parameters | Trevi Therapeutics Inc | Sage Therapeutics Inc | Applied Therapeutics Inc | Newron Pharmaceuticals US Inc |
|---|---|---|---|---|
| Headquarters | United States of America | United States of America | United States of America | United States of America |
| City | New Haven | Cambridge | New York | Morristown |
| State/Province | Connecticut | Massachusetts | New York | New Jersey |
| No. of Employees | 25 | 487 | 25 | - |
| Entity Type | Public | Public | Public | Private |
Key Financial Charts
Sales Growth
Net Income Growth
Executives
| Name | Position | Board | Since | Age |
|---|---|---|---|---|
| David Meeker | Chairman | Executive Board | 2017 | - |
| Jennifer Good | Chief Executive Officer; President; Director | Executive Board | 2011 | - |
| Lisa Delfini | Chief Financial Officer | Senior Management | 2021 | - |
| David Clark | Chief Medical Officer | Senior Management | 2022 | - |
| Thomas Sciascia | Chief Scientific Officer | Senior Management | - | - |
| Non Dignissim Eros | Proin vel | Convallis | 2024 | XY |
| Non Dignissim Eros | Proin vel | Convallis | 2024 | XY |
| Non Dignissim Eros | Proin vel | Convallis | 2024 | XY |
Still looking?
Have you found what you were looking for? From start-ups to market leaders, uncover what they do and how they do it.
Explorer
Access more premium companies when you subscribe to Explorer